Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour

État Nombre total Résumé
Négociations actives 44 Non liées à l’oncologie: 27
Liées à l’oncologie: 17
Négociations envisagées 15 Non liées à l’oncologie: 12
Liées à l’oncologie: 3
Négociations terminées 781 Avec lettre d’intention: 675
Sans entente: 106
Négociations qui n’ont pas eu lieu 108

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Ojjaara GlaxoSmithKline Inc. For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Balversa Janssen Inc. Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior th
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion
Filra Jamp Pharma Corporation Multiple Indications
Niopeg Nora Pharma Inc. To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di
Cosentyx Novartis Pharmaceuticals Canada Inc. Hidradenitis Suppurativa

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Xcopri Paladin Labs Inc. Epilepsy, partial-onset seizures
Xtandi Astellas Pharma Inc. ​For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)
Tyenne Fresenius Kabi Canada Ltd. Multiple Indications
Remdantry Celltrion Healthcare Canada Ltd. Multiple Indications
Epidiolex Jazz Pharmaceuticals Canada Inc. Dravet Syndrome (DS)
Epidiolex Jazz Pharmaceuticals Canada Inc. Seizures associated with Tuberous Sclerosis Complex (TSC)
Epidiolex Jazz Pharmaceuticals Canada Inc. Lennox-Gastaut Syndrome (LGS)
Osenvelt Celltrion Healthcare Canada Ltd. Multiple Indications
Stoboclo Celltrion Healthcare Canada Ltd. Multiple Indications
Libtayo Regeneron in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1
Libtayo Regeneron For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor
Libtayo Regeneron Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Elrexfio Pfizer Canada ULC Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines